Drug Trial Radar · NCT01681940
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
Last checked: Nov 20, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jan 2012
Primary completion
Aug 2012
Study completion Sep 2013
Sponsor
- Lead sponsor
- Zymenex A/SIndustry
- Sponsor type
- Industry
- Collaborators
- European Commission
- First posted
- Sep 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis
Conditions
- Alpha-Mannosidosis
Interventions
LamazymDrug
ERT, i.v. infusions weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of Oligosaccharides in blood serumTime frame: 6 months
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101
Brussels, Belgium
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
Copenhagen, Denmark
Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn
Córdoba, Spain
Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.